Therapeutics Company Shows Breakthrough Antibiotic Research Results

A Breakthrough in Antibiotic Research: Iterum Therapeutics' Phase 3 REASSURE Trial Shows Promising Results.

Disclaimer: This article contains affiliate links. If you purchase anything through these affiliated links, I may earn a commission.

In the ever-evolving field of pharmaceuticals, a significant breakthrough has been made by Iterum Therapeutics (NASDAQ: $ITRM). The company's Phase 3 REASSURE trial for their drug Sulopenem has met its primary endpoint of n…